Drug class
Antineoplastic differentiating agent; arsenical cytotoxic drug
Mechanism of action
In acute promyelocytic leukaemia (APL), arsenic trioxide promotes degradation of the PML-RARα fusion oncoprotein and induces differentiation and apoptosis of abnormal promyelocytes. Additional cellular effects contribute to antineoplastic activity.
General use cases
- Treatment of newly diagnosed low-risk acute promyelocytic leukaemia (APL) in combination with tretinoin
- Treatment of relapsed or refractory APL in product-specific regimens under specialist haematology care
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
